MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Vaxcyte Inc

Suletud

SektorTervishoid

36.24 -2.89

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

35.75

Max

37.65

Põhinäitajad

By Trading Economics

Sissetulek

-3.6M

-141M

Töötajad

414

EBITDA

-123M

-176M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+157.72% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

4. aug 2025

Turustatistika

By TradingEconomics

Turukapital

128M

4.7B

Eelmine avamishind

39.13

Eelmine sulgemishind

36.24

Uudiste sentiment

By Acuity

50%

50%

154 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Vaxcyte Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. märts 2025, 14:19 UTC

Suurimad hinnamuutused turgudel

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

3. sept 2024, 17:22 UTC

Peamised uudised

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

Võrdlus sarnastega

Hinnamuutus

Vaxcyte Inc Prognoos

Hinnasiht

By TipRanks

157.72% tõus

12 kuu keskmine prognoos

Keskmine 94.25 USD  157.72%

Kõrge 137 USD

Madal 65 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Vaxcyte Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

6

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

28.09 / 34Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

154 / 376 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.